Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.71 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.71 |
| ▸ | ITGAL | P20701 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642426 | 1.00 | ITGB2 (0.71) | ITGB2ICAM1ITGAL | |
| SCHEMBL7646849 | 0.92 | ITGB2 (0.74) | ITGB2ICAM1ITGAL | |
| SCHEMBL5196362 | 0.89 | ITGB2 (0.72) | ITGB2ICAM1ITGAL | |
| SCHEMBL5449287 | 0.87 | ITGB2 (0.69) | ITGB2ICAM1ITGAL | |
| SCHEMBL14362564 | 0.83 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL5447062 | 0.83 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL14066369 | 0.83 | ITGB2 (0.81) | ITGB2ICAM1ITGAL | |
| SCHEMBL4890594 | 0.83 | ITGB2 (0.81) | ITGB2ICAM1ITGAL | |
| SCHEMBL14362602 | 0.82 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL5451152 | 0.82 | ITGB2 (1.00) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234271-A1 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them | ICOS CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
| US-20070259863-A1 | Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives | ICOS CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1740561-A2 | ARYLPHENYLAMINO-AND ARYLPHENYLETHER-SULFIDE DERIVATIVES, USEFUL FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ICOS Corporation (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1740565-A2 | ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SUFIDE DERIVATIVES | ICOS Corporation (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105766-A2 | ARYLPHENYLAMINO-AND ARYLPHENYLETHER-SULFIDE DERIVATIVES, USEFUL FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ICOS CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105770-A2 | ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SULFIDE DERIVATIVES | ICOS CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259863-A1 | Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives | AHR, ARSA, TST | ITGB2 3194/4885ICAM1 1146/4885ITGAL 2966/4885 |
| US-20080234271-A1 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them | HPGDS, AHR, TST | ITGB2 3230/4885ICAM1 804/4885ITGAL 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.